Overview
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Description
Patients are recruited in the platform for the research purpose of 4 downstream projects. For more information, please have a look at the "Groups and cohorts" section.
Eligibility
- Patients with pathologically confirmed selected tumor types (at site or centrally);
- Mandatory availability of adequate human biological material (HBM);
- Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
- Age ≥ 12 years;
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
- Written informed consent according to applicable legal and ethical requirements;